Copyright: ©Author(s) 2026.
World J Gastrointest Oncol. Nov 15, 2026; 18(11): 123962
Published online Nov 15, 2026. doi: 10.4251/wjgo.123962
Published online Nov 15, 2026. doi: 10.4251/wjgo.123962
Figure 1 Design and patients enrolled in this study.
Reasons for exclusion during the 5-year follow-up included: Loss to follow-up (n = 42), self-discontinuation of treatment (n = 18), and development of decompensated cirrhosis (n = 9). HCC: Hepatocellular carcinoma; HBV: Hepatitis B virus; HCV: Hepatitis C virus; NAs: Nucleos(t)ide analogs; IFN: Interferon.
- Citation: Hao M, Liu CR, Zhang M, Zhou XQ, Jiang ZC, Gao XH, Zhang X, Wang WJ, Wang YK, Jia XL, Li YP, Dang SS. Interferon therapy reduces incidence of hepatocellular carcinoma in patients with high risk of hepatitis B virus-related hepatocellular carcinoma. World J Gastrointest Oncol 2026; 18(11): 123962
- URL: https://www.wjgnet.com/1948-5204/full/v18/i11/123962.htm
- DOI: https://dx.doi.org/10.4251/wjgo.123962